| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10988436 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11072577 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) | |
Cuvrior is owned by Orphalan.
Cuvrior contains Trientine Tetrahydrochloride.
Cuvrior has a total of 2 drug patents out of which 0 drug patents have expired.
Cuvrior was authorised for market use on 28 April, 2022.
Cuvrior is available in tablet;oral dosage forms.
Cuvrior can be used as a method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine.
The generics of Cuvrior are possible to be released after 03 May, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 28, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET;ORAL
CUVRIOR family patents
